FDA plans to write guidance to clarify for sponsors when accelerated approval is appropriate and to revisit the standards of evidence needed to support that approval pathway as congressional interest grows in expanding the program.
The program for speeding approval of drugs before the full extent of the efficacy and safety is known has been very successful for drugs to treat HIV and cancer and some other diseases, but “we think that it’s underutilized in many areas,” Center for Drug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?